BioTuesdays

Category - Markets

iTeos Logo
Markets

HCW starts iTeos Therapeutics at buy; PT $37

H.C. Wainwright launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with a “buy” rating and $37 price target. The stock finished at $23.03 on May 4. ITeos Therapeutics, which is developing next-generation immuno...

May 5, 2021
Markets

BTIG starts Mereo Biopharma at buy; PT $10

BTIG initiated coverage of Mereo Biopharma (NASDAQ:MREO) with a “buy” rating and price target of $10. The stock closed at $3.49 on May 4. “We believe Mereo shares are significantly undervalued with abundant proof-of...

May 5, 2021
Markets

Maxim doubles BioLineRx PT to $10 from $5

Maxim Group raised its price target for BioLineRx (NASDAQ:BLRX) to $10 from $5 on positive top-line data from the company’s Phase 3 GENESIS trial. The stock was quoted at $5.30, up $2.11, in afternoon trading on...

May 4, 2021
Markets

SVB Leerink starts VectivBio at OP; PT $28

SVB Leerink launched coverage of VectivBio Holding AG (NASDAQ:VECT) with an “outperform” rating and $28 price target. The stock closed at $15.21 on May 3. VectivBio is focused on developing treatments for severe rare...

May 4, 2021
Lucira-Health-Logo
Markets

WB cuts Lucira Heath to market perform

William Blair downgraded Lucira Health (NASDAQ:LHDX) to “market perform,” citing changes to the testing market that have played out over the last couple of months coupled with lack of demand for the company’s at-home...

May 4, 2021
Markets

Stifel starts ProQR Therapeutics at buy; PT $20

Stifel initiated coverage of ProQR Therapeutics N.V. (NASDAQ:PRQP) with a “buy” rating and price target of $20. The stock finished at $6.22 on April 30. “As a clinical-stage company with demonstrated proof-of-concept...

May 3, 2021
AVROBIO
Markets

SVB Leerink cuts AVROBIO PT to $10 from $18

SVB Leerink reduced its price target for AVROBIO (NASDAQ:AVRO) to $10 from $18 but maintained its “market perform” rating after the company announced that it may no longer pursue an accelerated approval pathway for AVR...

May 3, 2021
Markets

Cantor starts Clene at OW; PT $22

Cantor Fitzgerald launched coverage of Clene (NASDAQ:CLNN) with an “overweight” rating and 12-month price target of $22. The stock closed at $9 on April 30. Clene is a neuro-innovator that is developing drugs to enhance...

May 3, 2021
DermTech-Logo
Markets

BTIG starts DermTech at buy; PT $53

BTIG initiated coverage of DermTech (NASDAQ:DMTK) with a “buy” rating and $53 price target. The stock closed at $42.05 on April 30. DermTech provides genomic diagnostic testing for various skin diseases and conditions...

May 3, 2021
SioGene
Markets

HCW starts Sio Gene Therapies at buy; PT $8

H.C. Wainwright initiated coverage of Sio Gene Therapies (NASDAQ:SIOX) with a “buy” rating and price target of $8. The stock closed at $2.70 on April 29. Sio is a gene therapy company with significant experience and...

April 30, 2021